The global human microbiome market is expected to account for USD 273.40 million, registering a CAGR of about 22.6% during (2019-2025) (henceforth, referred to as the forecast period), the market is also expected to reach USD 757.26 million by 2025.
Increasing Incidence of Lifestyle Diseases
The rising incidence of lifestyle diseases globally is a strong driver of the microbiome market, as therapeutics may provide an alternative route to tackle significant healthcare challenges such as obesity. The increasing occurrence of autoimmune disorders and antibiotic resistance are also important areas which are in great need of fresh treatment approaches, and for which microbiome therapies may have a significant impact over the next few years. With advancements in precision medicine, personalized nutrition is also playing a crucial role. Microbiome technologies strive for novel developments in the area. Almost half of the total chronic disease deaths are attributable to cardiovascular diseases; obesity and diabetes are also showing worrying trends, not only because they already affect a large proportion of the population, but also because they have started to appear earlier in life. Hence, this exorbitant increase in the lifestyle diseases across the globe is driving the market for the human microbiome and is expected to augment the market in the future. The other factor such as rising geriatric population and increasing R&D investments is driving the market.
Stringent Government Regulations
The science is advancing rapidly, with more and more scientists excited about the potential and potency of fecal matter and the microbes in it. The FDA regulations on these procedures, however, keep them out of reach for most patients: Since 2013, the agency has banned doctors from doing fecal transplants on anything except Clostridium Difficile (C. diff). Stringent government regulations pertaining to the approval of human microbiome-based therapies are creating a major impediment to the growth of the market. The use of technology employing knowledge of the human microbiome is just getting started and is not yet widely applied. Nevertheless, it is important to consider the ethical issues early on so that we may try to avoid at least those pitfalls that can be identified now rather than waiting for disasters to occur and then trying to cobble together hasty responses. Fresh consideration of these issues by the biomedical research community, eschewing both exaggerations of the risks and ignoring real issues, will require both clear thinking and courage. So, the strict regulatory policies are hindering the growth of the market. The other factors such as lack of comprehensive research are restraining the market.
US has the Highest Market Share
In North America, US is dominating the human microbiome market due to the increasing geriatric population and rising prevalence of diseases are the major factors for the highest market share of this region. Asia-Pacific is expected to record the substantial growth the forecast period due to the owing to the improving research infrastructure in the region.
Key Developments in the Market:
- February 2018: Yakult Danone India, a 50:50 joint venture between Yakult Honsha and Danone, has released the latest variant on its signature probiotic drink, called as Yakult Light; which contains vitamin D and E.
- October 2017: Enterome, has launched the EB8018, which is a small molecule designed to block FimH, as a potential new orally-administered treatment for Crohn’s disease.
- Enterome Bioscience
- Seres Therapeutics
- Vithera Pharmaceuticals
- Second Genome Inc.
- Synthetic Biologics Inc.
- Vedanta Biosciences Inc.
- Osel Inc.
- Synlogic Inc.
Reasons to Purchase this Report:
- Current and future human microbiome market outlook in the developed and emerging markets
- Analyzing various perspectives of the market with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, market shares and strategies employed by the major market players
- 3 months analyst support along with the Market Estimate sheet (in excel)
This report can be customized to meet your requirements. Please contact us for more information.
This report will be delivered within 2 business days.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product & Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Rising Incidence of Lifestyle Diseases
6.1.2 Growing Geriatric Population
6.1.3 Increasing R&D Investments
6.2 Market Restraints
6.2.1 Lack of Comprehensive Research
6.2.2 Stringent Government Regulations
6.4 Key Challenges
7. Market Segmentation
7.1 By Product Type
7.2 By Disease Indication
7.2.4 Diabetes and Obesity
7.3 By Geography
7.3.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 Australia & New Zealand
126.96.36.199 South Korea
188.8.131.52 Rest of Asia-Pacific
7.3.4 Middle East & Africa
184.108.40.206 South Africa
220.127.116.11 Rest of the Middle East & Africa
7.3.5 South America
18.104.22.168 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Enterome Bioscience
9.4 Seres Therapeutics
9.5 Vithera Pharmaceuticals
9.6 Second Genome, Inc.
9.7 Synthetic Biologics, Inc.
9.8 Vedanta Biosciences, Inc.
9.9 Osel Inc.
9.10 Synlogic, Inc.
10. Future of the Market